Clinical Trials Browser

OTHER_GOV × Bortezomib × Lymphoid × Clear all

NCT04433156 2023-05-18

VR-CAP in the First-line Treatment for Patients With Marginal Zone Lymphoma

Phase 2 Unknown

Lymphoma, B-Cell, Marginal Zone

NCT05137860 2022-01-18

Efficacy of the Use of Bortezomib for the Treatment of Relapsed Leukemia or Positive MRD

Phase 4 Unknown

LymphoidOther hematologic neoplasm

Recurrence, Neoplasm, Residual, Precursor Cell Lymphoblastic Leukemia-Lymphoma